Skip to content
City PM
  • Germany
  • France
  • Europe
  • Markets
  • Business
  • Opinion
  • DE
  • Germany
  • France
  • Europe
  • Markets
  • Business
  • Opinion
  • DE
Monday 01 June 2015 6:33 am

On the path to curing cancer: Scientists say immunotherapy could open a “new era” of treatment

By: Sarah Spickernell

Add as a preferred source on Google

For decades, chemotherapy has been the main treatment used to prolong the lives of cancer sufferers, but scientists believe a new kind of treatment could completely transform how we tackle the disease.
 
Immunotherapy, which involves harnessing the body's own immune system to attack cancerous cells in the same way it would attack a virus, is able to completely stop cancer in its tracks in more than half of cases. 
 
It's given to patients in the form of a combination therapy of two drugs –  ipilimumab and nivolumab, and in an international trial they were found to prevent skin cancer from advancing for at least a year in 58 per cent of cases. 
 
At a conference in Chicago scientists heralded these results as “spectacular”, since chemotherapy drugs tend to offer much smaller improvements in health, giving sufferers just months and in some cases weeks of extra life. 
 
Professor Peter Johnson, director of medical oncology at Cancer Research UK, said: "The evidence suggests we are at the beginning of a whole new era for cancer treatments." 
 
His colleague, Dr Alan Worsley, added that the drugs could “release the brakes on the immune system while blocking cancer's ability to hide from it."
 
He added, however, that treatments should be combined with caution, since the practice can increase the chance of suffering sever side effects: "Identifying which patients are most likely to benefit will be key to bringing our best weapons to bear against the disease."

Share this article

  • Facebook
  • X
  • LinkedIn
  • WhatsApp
  • Email

Similarly tagged content:

Sections

  • News

Categories

  • Tech

Trending Articles

  • Why Fifa World Cup players are drowning in commercial red tape

  • Europe has made a ‘major mistake’ on slow electrification, IEA chief warns 

  • Sadiq Khan lobbies Burnham to appoint Miliband as Chancellor 

  • Apple sues Open AI accusing them of stealing ‘trade secrets’

  • Will the Nations Championship financially underdeliver for in-need Fiji?

More from City PM

  • Araris Biotech AG and Taiho Oncology Announce Dosing of First Patient in Phase 1 Trial of ARC-02, a Novel ADC for the Treatment of Non-Hodgkin Lymphoma

    Business Wire
  • GSK shares slip after buying US cancer treatment firm Nuvalent for $10.6bn

    Pharma
    GSK logo displayed prominently, signifying the companys presence and relevance in the business and healthcare sectors.
  • Patent cliff fuels Novartis’ $1.5bn swoop for London biotech

    Healthcare
    Hikma produces generic drugs
  • Leo Cancer Care Raises $65M Series D to Scale Its Integrated Upright Cancer Care Platform

    Business Wire
  • Book review: The Reverse Centaur’s Guide to Life After AI by Cory Doctorow

    Life&Style
    GettyImages 2240900371 portrays a significant business event with professionals networking in a modern conference setting.
  • Harley Street Health District Releases First Annual Impact Report

    Business Wire
  • Anocca has Dosed First Patients with Precision TCR-T Cell Therapy Targeting Mutant KRAS in Pancreatic Cancer

    Business Wire
  • Reply and IEO Launch Collaboration to Co-Develop and Train Domain-Specific Large Language Models for Oncology

    Business Wire

City PM — European politics, business and analysis.

Europe

  • Germany
  • France
  • Europe
  • UK & Ireland

Topics

  • Business
  • Markets
  • AI
  • Technology
  • Opinion
  • Energy

More

  • Politics
  • Economics
  • Fintech
  • Legal
  • Sport
  • Life

Company

  • About City PM
  • Editorial Policy
  • Corrections
  • Contact
  • Terms of Use
  • Privacy Policy
  • Cookie Policy
© 2026 City PM · Published by CityPM Media, Bahnhofstrasse 65, 8001 Zürich, Switzerland
About · Editorial Policy · Corrections · Contact · Privacy · Facebook